Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults

This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e. receptor binding and N-terminal domains). Heal...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2023-12, Vol.19 (1), p.2190690
Main Authors: Yassini, Patrick, Hutchens, Mark, Paila, Yamuna D., Schoch, Lorraine, Aunins, Anne, Siangphoe, Uma, Paris, Robert
Format: Article
Language:English
Subjects:
2019-nCoV Vaccine mRNA-1273
Adult
Antibodies, Neutralizing
Antibodies, Viral
clinical study
Coronavirus
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Double-Blind Method
Humans
Immunogenicity, Vaccine
mRNA vaccines
RNA, Messenger
SARS-CoV-2
Severe acute respiratory syndrome coronavirus-2
vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e. receptor binding and N-terminal domains). Healthy adults aged 18-55 years (n = 104) were randomized (1:1:1:1:1) to receive two doses of mRNA-1283 (10, 30, or 100 µg) or mRNA-1273 (100 µg) administered 28 days apart, or a single dose of mRNA-1283 (100 µg). Safety was assessed and immunogenicity was measured by serum neutralizing antibody (nAb) or binding antibody (bAb) responses. At the interim analysis, no safety concerns were identified and no serious adverse events, adverse events of special interest, or deaths were reported. Solicited systemic adverse reactions were more frequent with higher dose levels of mRNA-1283 than with mRNA-1273. At day 57, all dose levels of the 2-dose mRNA-1283 regimen (including the lowest dose level [10 µg]) induced robust nAb and bAb responses that were comparable to those of mRNA-1273 (100 µg). mRNA-1283 was generally safe in adults, with all dose levels of the 2-dose regimen (10, 30, and 100 µg) eliciting similar immunogenicity as the 2-dose mRNA-1273 regimen (100 µg). Clinical Trials Registration: Clinicaltrials.gov, NCT04813796.
ISSN:2164-5515
2164-554X
2164-554X
DOI:10.1080/21645515.2023.2190690